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Objective: During coronary surgery, proximal vein graft anastomoses have been performed by using an aortic
partial occlusion clamp to allow for a hand-sewn anastomosis. The purpose of this multicenter, prospective, ran-
domized trial was to evaluate the efficacy of the PAS-Port device (Cardica, Inc, Redwood City, Calif), which
allows an automated proximal anastomosis to be performed without aortic clamping.
Methods: Between June 22, 2006, and March 22, 2007, 220 patients requiring coronary artery bypass grafting
with at least 2 vein grafts were enrolled. Within each patient, 1 graft was randomly assigned to receive a PAS-Port
device, and the other was assigned to receive a hand-sewn anastomosis to the ascending aorta. The primary end
point was angiographic patency (<50% stenosis) 9 months after surgical intervention. Secondary end points in-
cluded average time to complete each anastomosis and 9-month freedom from major adverse cardiac events.
Results: One hundred eighty-three patients received matched grafts that were angiographically assessed at 9
months. The 9-month graft patency was 82.0% (150/183) for hand-sewn and 80.3% (147/183) for PAS-Port
grafts. The patency rate of PAS-Port anastomoses was statistically noninferior to that of hand-sewn anastomoses
(95% lower confidence limit for difference,7.95%). The freedom from major adverse cardiac events at 9
months was 97.7% for PAS-Port (95% confidence interval, 94.5%–99.0%) and 98.2% for hand-sewn (95%
confidence interval, 95.1%–99.3%) grafts. The PAS-port device was associated with a 4.6 3.9–minute reduc-
tion in anastomotic time compared with that seen with a hand-sewn anastomosis (P< .001).
Conclusions: The PAS-Port proximal anastomotic device produces an effective anastomosis with a 9-month
patency rate that is comparable with that of a hand-sewn anastomosis. It allows for construction of a proximal
anastomosis without aortic clamping and requires less time than a hand-sewn anastomosis.E
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doi:10.1016/j.jtcvs.2009.02.017The Journal of Thoracic and Cgrafts to bypass other diseased vessels. Although arterial
revascularization might provide a more durable revasculari-
zation strategy,1,2 venous conduits are still commonly used.
For both venous grafts and arterial grafts not harvested in
situ, a proximal anastomosis to the ascending aorta must
be constructed in addition to a distal anastomosis to the cor-
onary artery target. This has traditionally required clamping
of the aorta to perform a hand-sewn anastomosis. However,
manipulation of the aorta with a partial occlusion (side-bit-
ing) clamp for off-pump procedures and a crossclamp with
or without a side-biting clamp for on-pump procedures can
be associated with aortic atheroemboli.3-5 Aortic manipula-
tion is independently associated with an increased risk of
postoperative stroke.6,7
Facilitating devices have been developed to allow for con-
struction of a proximal anastomosis without clamping the
aorta.8-10 These devices are commonly used during off-
pump procedures to allow for a no-clamp coronary bypass
procedure. However, these devices still require a hand-sewn
anastomosis to be performed between the graft and the aorta
and are associated with some blood loss. Hand-sewn anasto-
moses with these facilitating devices can be time-consuming,
increasing operative and anesthesia times. Furthermore,ardiovascular Surgery c Volume 138, Number 1 125
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FDA ¼ US Food and Drug Administration
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hand-sewn anastomoses are dependent on the particular
anatomy of the patient and the skills of the surgeon.
The PAS-Port Proximal Anastomosis System (Cardica,
Inc, Redwood City, Calif) was specifically designed to cre-
ate a consistent anastomosis between a saphenous vein and
the aorta during either on- or off-pump coronary bypass sur-
gery. It is a fully integrated, automated system that cuts the
aortotomy and attaches the vein graft to the aorta in seconds,
producing consistent and reproducible anastomoses inde-
pendent of surgical technique and skill.
The objective of this prospective, randomized, multicen-
ter trial (the Evaluation of the PAS-Port in Coronary Surgery
[EPIC] trial) was to evaluate the safety and efficacy of the
PAS-Port System in creating a clampless proximal aortic
connection and to compare the patency of PAS-Port anasto-
moses with that of anastomoses constructed by using a stan-
dard hand-sewn technique with an aortic clamp.
MATERIALS AND METHODS
Compliance, Ethical Review, and Informed Consent
The study protocol was designed to assess the patency of the index grafts
and document any adverse effects related to device use. The study was con-
ducted in accordance with current Good Clinical Practices and the ethical
principles of theDeclaration ofHelsinki. The study protocol and amendments,
the subject information/consent form, and any materials used to recruit sub-
jects were submitted to and approved by institutional review boards in the
United States or independent ethics committees in Germany (European
Union). Before the start of the study, approval was obtained in compliance
with the requirements of the Clinical Investigation ofMedical Devices for Hu-
man Subjects. All patients signed informed consent forms before enrollment.
Study Design
This study was a prospective, randomized, multicenter trial conducted in
12 hospitals in the European Union and the United States. Two hundred
twenty subjects were enrolled with the intention to place at least 2 aortocoro-
nary venous bypass grafts. The revascularization strategy for these graftswas
determined preoperatively and confirmed intraoperatively before randomi-
zation. After satisfying all intraoperative inclusion criteria, including that
both vein segments were within specifications for use with the PAS-Port de-
vice, the randomization envelope was opened. The 2 saphenous vein graft–
coronary target pairings were identified as grafts 1 and 2 and assigned to one
of 2methods for creation of the anastomosis: the hand-sewn control group or
the PAS-Port treatment group. The randomization strategy for assignment of
the anastomotic method to the 2 index saphenous vein grafts was conducted
by using a randomnumber generator. The randomization envelope contained
a 6-digit alphanumeric number that was documented on the case report form.
With this information, the surgeon was instructed as to which type of anas-
tomotic technique to use for each of the 2 index grafts.
Both on-pump and off-pump surgical procedures were allowed at the dis-
cretion of each investigator/surgeon. Facilitating devices (eg, the Maquet
Heartstring, Maquet Cardiovascular LLC, San Jose, Calif, or the Novare En-
close, NovareSurgical Systems, Inc, Cupertino,Calif) were allowed for the ex-
ecution of the hand-sewn index proximal anastomoses to avoid the need for126 The Journal of Thoracic and Cardiovascular Surgaortic clamping in subjects undergoing off-pump coronary artery bypass at
the surgeon’s discretion. Intraoperative graft patency was evaluated based on
transit time Doppler blood flow measurements. Patients were asked to return
for follow-upvisits at 3 and9months after the operation.Acoronary angiogram
wasperformed at 9months after the operation to document indexgraft patency.
Study Population
The study population consisted of male and female patients, 50 to 85
years of age, who required nonemergency bypass of at least 2 coronary
arteries. Patients were required to have an ejection fraction of greater than
30%, as measured bymeans of ventriculographic analysis, nuclear imaging,
or echocardiographic analysis. Patients were required to have native coro-
nary artery stenosis of greater than 70% in each on the intended index grafts.
Exclusion criteria included the following: previous cardiac surgery, dialy-
sis-dependent renal failure, serum creatinine value of greater than 2.3 mg/
dL within 30 days before the operation, need for ongoing immunosuppres-
sive therapy, New York Heart Association class IV heart failure symptoms,
presence of systemic infection, preoperative intra-aortic balloon counterpul-
sation, aspirin allergy, history of thromboembolic disease requiring antico-
agulation therapy, cerebrovascular accident within 2 weeks before the
operation, and life expectancy of less than 1 year.
Populations for Analysis
Successfully treated patients who (1) had 2 grafts randomized, (2) com-
pleted the 9-month angiogram, and (3) had both index grafts (matched pair)
studied angiographically at 9 months and were assessable by the angio-
graphic core laboratory constituted the per-protocol population. The
intent-to-treat population consisted of patients who had 2 grafts randomized,
regardless of whether the grafts were successfully anastomosed to the aorta.
For patency, this included all patients with and without 9-month angio-
grams. For safety, this included all patients regardless of when the subject’s
grafts were censored. The as-treated population included all randomized
patients regardless of the method used for the proximal anastomosis or
whether the anastomotic methods were successful.
Intraoperative Data Collection
During the surgical procedure, the time to complete the proximal hand-
sewn anastomoses, time to use facilitating devices, and loading and deploy-
ment time for the PAS-Port system were recorded. All patients received
standard anticoagulation management with heparin and protamine reversal
in the operating room.
Surgical Technique
Any concomitant procedures, as well as any other planned nonindex
grafts, were performed at the discretion of the surgeon while adhering to
the following general guidelines: (1) partial occlusion clamps were not to
be placed on the aorta after the PAS-Port anastomosis was created; (2) all
proximal anastomoses were to be completed first before completing any dis-
tal anastomoses; and (3) facilitating devices were permitted (eg, the Maquet
Heartstring or Novare Enclose) for the hand-sewn anastomosis but were to
be used and removed before deployment of the PAS-Port Anastomosis
System. Different techniques were permitted and documented and included
off-pump coronary artery bypass, beating heart supported with cardiopul-
monary bypass, and traditional on-pump coronary artery bypass with cardi-
oplegic arrest. Different saphenous vein harvesting techniques were also
documented and included endoscopic techniques, bridging skin incisions,
or open continuous incisions.
The PAS-Port device (Figure 1) was designed to allow surgeons to load the
bypass graft and rapidly complete an automated anastomosis. This device cre-
ates the aortotomy and attaches the vein graft to the aorta by means of an au-
tomated mechanism, all housed in a single unit. This mechanism allows for
a proximal aortic anastomosis to be completed without aortic clamping. Com-
pared with earlier devices, the PAS-Port system allows the endothelium of theery c July 2009
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thermore, there is no foreign material left within the graft lumen.
End Points
Primary end points. The primary end point in this study was
patency of the proximal anastomoses of the index grafts assessed by means
of angiographic analysis at 9 months after the operation in the per-protocol
population. In this study patency was defined as less than 50% stenosis
(FitzGibbon A) in the proximal anastomosis of the index graft.11
Secondary end points. Patency analyses were also conducted for
the intent-to-treat and as-treated populations. In addition, safety analyses
were conducted for the intent-to-treat population. The safety analysis in-
cluded the occurrence and frequency of adverse events at 30 days postoper-
atively and 9 months. The 9-month freedom from major adverse cardiac
events (MACEs) was reported as a Kaplan–Meier curve and compared
with the available published literature. MACEs were defined as death, myo-
cardial infarction, or target vessel revascularization associated with either
a PAS-Port or hand-sewn index graft. The investigators, the medical mon-
itor, the adjudication committee, and, in instances of subject death, the Data
Safety Monitoring Board, were responsible for reviewing all severe adverse
events and determining whether they were device related.
The acute procedural success rate was determined for both index grafts in
the intent-to-treat population. This rate calculated the percentage of grafts suc-
cessfully anastomosed by using each method. An unsuccessful anastomosis
with either method was defined as one of the following: (1) device or surgical
technical failures that resulted in a PAS-Port implant not being successfully
placed during the procedure (successful implantation with a second PAS-
Port device was considered a procedural success); (2) a complication that
resulted in a PAS-Port implant having to be removed before the subject’s dis-
charge; or (3) failure to complete a hand-sewn index graft for any reason.
The time to complete the proximal hand-sewn anastomoses, time to use
facilitating devices, and time required to load and deploy the PAS-Port sys-
tem were recorded. All patients received 81 mg of aspirin daily for the
duration of the study. Clopidogrel, 75 mg administered orally, was initiated
on postoperative day 1 and continued for 90 days. Additional treatment was
administered at the discretion of referring cardiologists.
Angiographic Core Laboratory Analysis
The primary goal of the analysis by the core laboratory was to indepen-
dently assess index graft patency at the proximal anastomosis. The core
laboratory was blinded to investigative site qualitative analyses and re-
ported patency of the index graft proximal anastomoses according to Fitz-
Gibbon criteria.11 Based on the protocol definition of patency, a patent
proximal anastomosis was defined as an anastomosis classified by the
core laboratory as FitzGibbon A. Anastomoses with a FitzGibbon B or
FitzGibbon O classification were considered occluded. Grafts considered
grade A according to Fitzgibbon criteria had excellent graft flows with un-
impaired runoff and proximal anastomotic stenosis of less than 50%. The
core laboratory quantitatively determined the amount of proximal anasto-
mosis stenosis by subtracting the minimum internal graft diameter at the
proximal anastomosis from the average internal graft diameter approxi-
FIGURE 1. PAS-Port device.The Journal of Thoracic andmately 2 to 5 cm distal to the proximal anastomosis and dividing this
over the average internal graft diameter approximately 2 to 5 cm distal to
the proximal anastomosis (Figure 2). In addition, the core laboratory re-
ported any abnormalities found in the index grafts or anastomoses, as
well as the maximum native stenosis of the target vessel or its tributaries
to which the index grafts supplied blood. For subjects unwilling or unable
to undergo the protocol-defined 9-month angiogram, efforts were made to
obtain multislice computed tomographic angiographic analysis. Because of
the limited image resolution of computed tomographic analysis when com-
pared with digital angiographic analysis, assessment of the proximal anas-
tomosis was binary: patent or occluded.
Statistical Methods
The primary efficacy analysis used the per-protocol population. Only
grafts with a matched pair (both a successful PAS-Port and hand-sewn graft
in the same patient) were included in this analysis. The primary statistical ob-
jective was to test the noninferiority of the 9-month patency rate of the prox-
imal anastomoses performedwith the PAS-Port index grafts versus those that
were hand-sewn. Noninferiority was defined by a lower limit of the 95% con-
fidence interval for the success difference (PAS-Port implant minus conven-
tional hand-sewn anastomosis) being greater than10%. With a significance
level of .05, a standard proportion of 0.85, an equivalence limit difference of
0.10, and a power of 80%, the minimum number of subjects with angio-
graphic follow-up was calculated to be 158. Assuming that 80% of the sub-
jects would return for angiographic follow-up, a total of 198 subjects needed
to be discharged after undergoing successful bypass with the PAS-Port im-
plant and a hand-sewn index graft. A second primary statistical objective
was to provide a 95% lower confidence limit for the point estimate of the an-
giographically determined patency rate at 9 months. Specifically, the US
Food and Drug Administration (FDA) required that device efficacy would
be established only if the lower confidence limit for the point estimate of
PAS-Port graft patency at 9 months was at least 70%.
Secondary end points included acute procedural success rate and as-
treated and intent-to-treat analyses, all of which were evaluated by using
inferential statistics without a formal statistical hypothesis. All statistical pro-
cessing was performed with SAS software (SAS Institute, Inc, Cary, NC).
RESULTS
This prospective randomized study included 12 investiga-
tional sites with enrollment from June 22, 2006, to March
23, 2007; 8 of the sites were located in the United States,
FIGURE 2. A, Internal diameter (in millimeters) of the saphenous vein
graft at the proximal anastomosis. C, Average internal diameter of the graft
2 to 5 cm distal to proximal anastomosis: Stenosis of proximal anastomosis
ð%Þ ¼ ½ðCAÞ=C 3100:Cardiovascular Surgery c Volume 138, Number 1 127
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Evolving Technology/Basic Science Puskas et alFIGURE 3. Flow diagram of patients in the per-protocol population who had core laboratory angiographic analysis and matched pair comparisons. CT,
Computed tomography.and 4 were in the European Union. Five hundred eighty-nine
patients were screened for the study, and 249 met the preop-
erative inclusion and exclusion criteria (Figure 3). Twenty-
nine (11.7%) did not meet the intraoperative inclusion
criteria and were withdrawn from the study. Patient demo-
graphics are presented in Table 1. Of the 220 eligible
subjects who participated in the surgical procedure, the
PAS-Port systemwas successfully deployed in 211 (Figure 3
and Table 2). Overall, 188 (85.5%) of 220 of the patients
with PAS-Port anastomoses and 192 (87.3%) of 220 of
the patients with hand-sewn anastomoses completed the
study with 9-month angiographic follow-up (Figure 3). Be-
cause of the way in which the per-protocol group was
defined, there were no acute procedural failures and no anas-
tomotic conversions included in this population. Therefore
183 patients met the per–protocol cohort definition, were
successfully treated, and had matched anastomosis pairs
assessed by the angiography core laboratory.
The graft patency results from the angiographic core lab-
oratory analysis (FitzGibbon Grade A) in the per-protocol
cohort demonstrated an average 9-month patency for
hand-sewn grafts of 82.0% (150/183; lower confidence
bound, 76.6%) and 80.3% (147/183; lower confidence
bound, 74.9%) for grafts attached to the aorta with the128 The Journal of Thoracic and Cardiovascular SuPAS-Port System. The patency rate of PAS-Port anastomo-
ses was statistically noninferior to the success rate of the
hand-sewn anastomoses, with a lower limit of the 95% con-
fidence interval for the difference between the 2 treatment
groups of 7.95% (primary objective). The lower confi-
dence bound for the average PAS-Port patency in this cohort
was 74.9%, which exceeded the FDA-required minimum
lower confidence bound of 70% (secondary objective). In
addition, the acute procedural success rate in the study was
95.9%, which exceeded the target of 90%.
In the intent-to-treat cohort 9-month angiographic pa-
tency was comparable in both groups (PAS-Port, 80.6%
[150/186; lower confidence bound, 75.26%]; hand-sewn,
82.2% [157/191; lower confidence bound, 77.02%]). In
the as-treated analysis the patency rate was comparable be-
tween groups, with an angiographic patency of 80.4%
(148/184; lower confidence, bound 75.0%) for PAS-Port
grafts versus 82.4% (159/193; lower confidence bound,
77.3%) for hand-sewn grafts.
Major Adverse Cardiac Events
Safety analyses were conducted in the intent-to-treat pop-
ulation. The 9-month freedom fromMACEs was reported as
a Kaplan–Meier curve (Tables 3 and 4) and compared withrgery c July 2009
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recorded, which included 9 deaths (Table 5), 6 myocardial
infarctions, and 12 target vessel revascularizations, as
reported above. The majority of MACEs were related to tar-
get vessel revascularization (12 [44%]), 4 (33%) of which
were possibly related to the use of the PAS-Port system,
and 8 (67%) of which were possibly related to the index
TABLE 1. Patient demographics
Variable Total (n ¼ 220)
Age (y), mean  SD 68.1  7.3
BMI (kg/m2), mean  SD 28.8  4.5
Male, n (%) 171 (77.7)
History of smoking, n (%) 90 (40.9)
Diabetes mellitus, n (%) 81 (36.8)
Type I, n (%) 2 (0.9)
Type II, n (%) 79 (35.9)
Hyperlipidemia, n (%) 160 (72.7)
Hypertension, n (%) 189 (85.9)
Renal insufficiency, n (%) 18 (8.2)
Chronic lung disease, n (%) 17 (7.7)
Peripheral vascular disease, n (%) 46 (20.9)
Cerebrovascular accident, n (%) 15 (6.8)
Prior myocardial infarction, n (%) 76 (34.5)
Arrhythmia, n (%) 20 (9.1)
CCS class, n (%)
0 44 (20.0)
I 35 (15.9)
II 82 (37.3)
III 58 (26.4)
IV 1 (0.5)
NYHA class, n (%)
I 51 (23.2)
II 110 (50.0)
III 57 (25.9)
IV 2 (0.9)
Ejection fraction (%, mean  SD) 56.5  12.2
EuroSCORE (% chance of mortality) 3.3  3.7
Left internal artery graft use, n (%) 206 (93.6)
Off-pump coronary artery bypass, n (%) 140 (63.6)
Cardiopulmonary bypass time (min), mean  SD 100.7  36.4
Crossclamp time (min), mean  SD 63.1  32.4
Vein grafts, mean  SD 2.1  0.4
Arterial grafts, mean  SD 1.0  0.3
SD, Standard deviation; BMI, body mass index; CCS, Canadian Cardiovascular Soci-
ety; NYHA, New York Heart Association.The Journal of Thoracic andhand-sewn graft. Three (33%) of the 9 deaths were possibly
related to the use of the PAS-Port system; in none, however,
was a clear relationship established. One of the deaths was
possibly related to the hand-sewn index graft. Myocardial
infarction occurred in 6 subjects, which accounted for
22% of all MACEs. One of the myocardial infarctions might
possibly have been related to the use of the PAS-Port system
because the PAS-Port index graft was found to be occluded
in the 9-month surveillance angiographic analysis. Four pa-
tients had a stroke during the course of the study (2 on-pump
and 2 off-pump patients), 3 in the early postoperative period.
In all of these patients, an aortic clamp was used for con-
struction of the hand-sewn proximal anastomosis.
The 30-day and 9-month mortality rates in the patients
enrolled in the EPIC trial were 1.4% and 4.1%, respec-
tively. The 30-day and 9-month incidence of myocardial
infarction was 1.4% and 2.7%, respectively. The 30-day
and 9-month incidence of target vessel revascularization
was 0.9% and 2.7%, respectively.
Time Studies
The time required to load and deploy a PAS-Port device
was compared with the time required to complete a hand-
sewn anastomosis (by using the partial occlusion clamp
technique or facilitating devices). Significantly less time
was required to load and deploy the PAS-Port device com-
pared with side-biting or facilitating hand-sewn anastomo-
ses (Table 6).
Additional Patency Data
Patency was also defined according to the criteria used
for Project of Ex Vivo Vein Graft Engineering via Transfec-
tion (PREVENT) IV (patency defined as stenosis,<75%).12
Based on these definitions, patency for grafts in the per-pro-
tocol cohort was 84.7% (155/183) with the PAS-Port sys-
tem and 83.6% (153/183) for hand-sewn anastomoses.
Patency data according to surgical procedure and harvesting
technique were also available (Table 7)12 and were compa-
rable among the off-pump (83.3% [246/295]), on-pump
with cardioplegic arrest (86.6% [112/129]), and beating-
heart on-pump (84.2% [19/23]) groups. However, vein graft
patency was greater in those patients with veins harvested by
using the open technique (90.8%, 130/143) compared withTABLE 2. Reasons for PAS-Port failures
Reasons No.
Total grafts randomized to receive
a PAS-Port (n ¼ 220)
Converted to hand-sewn
anastomosis
Inability to evert vein graft onto implant (not deployed) 5 2.3% 4
Implant accidentally dislodged 2 0.9% 2
Side branch at implant impeded blood flow and required
conversion to hand-sewn anastomosis
1 0.5% 1
Graft attached in wrong direction to implant 1 0.5% 0
Total 9 4.1% 7Cardiovascular Surgery c Volume 138, Number 1 129
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ing (79.2%, 183/231).
DISCUSSION
Proximal vein graft anastomoses to the ascending aorta
are a routine part of coronary artery bypass procedures.
This has traditionally involved the use of an aortic clamp
to allow a bloodless field during construction of the proximal
anastomosis. For on-pump coronary procedures, surgical
options include performing proximal anastomoses under
a single cross-clamp during cardioplegic arrest or placing
a partial occlusion clamp after releasing the crossclamp.
For off-pump techniques, alternatives include using a partial
occlusion clamp or a no-clamp technique with facilitating
devices, such as the Maquet Heartstring or Novare En-
close.9,10 The impetus for these innovations was to minimize
aortic manipulation, which is a well-established risk factor
for atheroemboli and stroke.4-7 These devices provide a valu-
able option by allowing a proximal anastomosis to be per-
formed on a suitable portion of the aorta without the need
for an aortic clamp. However, these facilitating devices still
require the performance of a hand-sewn anastomosis, which
might be more technically challenging and involve more
blood loss than a conventional anastomosis on a clamped
aorta.
Proximal anastomotic connectors were developed to al-
low for an automated sutureless proximal anastomosis with-
out the use of an aortic clamp. The St Jude Symmetry device
(St Jude Medical, Inc, St Paul, Minn) was one of the first de-
vices to gain approval. After a period of initial enthusiasm,13
reports emerged documenting early graft stenoses and an un-
acceptably high incidence of early MACEs with these de-
vices.14-16 These results were attributed to excess foreign
body within the graft lumen and endothelial damage during
loading and deployment. Ultimately, this device was with-
drawn from the market in 2004. The Cardica PAS-Port de-
TABLE 3. Nine-month freedom from MACE rate by population
(Kaplan–Meier estimates)
3 mo 9 mo
Rate 95% CI Rate 95% CI
Intent-to-treat 94.5 90.6–96.9 91.6 86.9–94.6
Per protocol 96.7 92.8–98.5 94.9 90.4–97.3
CI, Confidence interval.
TABLE 4. Nine-month freedom from MACE rate by technique
(Kaplan–Meier estimates)
3 mo 9 mo
Rate 95% CI Rate 95% CI
PAS-Port 98.2 95.2–99.3 97.7 94.5–99.0
Hand-sewn 98.6 95.8–99.6 98.2 95.1–99.3
CI, Confidence interval.130 The Journal of Thoracic and Cardiovascular Suvice minimizes the amount of foreign body by limiting the
clips to the anastomosis site without exposure to the graft lu-
men. Similarly, the endothelium is not damaged because it is
not exposed to the device during loading and deployment.
Early and midterm results of the PAS-Port device have
been encouraging,17 with comparable patency rates between
the PAS-Port and hand-sewn groups. However, larger mul-
ticenter studies have not been conducted to compare patency
outcomes between these 2 techniques.
In this prospective, randomized, multicenter trial, the 9-
month patency of venous grafts that received a PAS-Port
device was statistically noninferior to those that were
hand-sewn. In the intent-to-treat and as-treated analyses,
TABLE 5. Causes of death for patients not completing the 9-month
follow-up
Patient
Time to death
(postoperative
days) Cause of death
Cardiac-
related
death
1 56 Lymphoma No
2 209 Lung cancer No
3 115 Left ventricular
dysfunction after
kinking of hand-sewn
index graft
Yes
4 33 ARDS No
5 82 Myocardial infarct Yes
6 8 Left ventricular
dysfunction after early
occlusion of LITA–
LAD bypass as
the major contributor
to subject death
Yes
7 255 Pneumonia No
8 9 Acute type A aortic
dissection
Yes
9 2 Left ventricular
dysfunction after early
occlusion of LITA–
LAD bypass as
the major contributor
to subject death
Yes
ARDS, Acute respiratory distress syndrome; LITA, left internal thoracic artery; LAD,
left anterior descending coronary artery.
TABLE 6. Time studies
Anastomosis times by technique
Time (min),
mean ± SD
PAS-Port loading and deployment (vs side-biting) 3.1  2.5
Hand-sewn side-biting 7.7  2.9
PAS-Port time savings (vs side-biting)* 4.6  3.9
PAS-Port loading and deployment (vs facilitating) 4.1  2.0
Hand-sewn facilitating 9.5  3.5
PAS-Port time savings (vs facilitating)* 5.5  3.9
SD, Standard deviation. *P< .001.rgery c July 2009
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the PAS-Port and hand-sewn anastomoses. Furthermore,
use of the PAS-Port system resulted in a time savings of
approximately 5 minutes compared with the use of an aortic
partial occlusion clamp or facilitating device. Vein graft pa-
tency in both the PAS-Port and hand-sewn anastomoses was
comparable with that seen in other recent studies.12,18-20 In
our analysis vein graft patency was comparable in the on-
and off-pump groups (86% vs 83%, respectively).
Use of the PAS-Port device requires a ‘‘proximals first’’
approach to grafting either on or off pump. Nonetheless,
the device proved relatively easy to use with a fairly short
learning curve. Even though most of the surgeons had not
used the device clinically before enrolling patients in the
study, the intraoperative rate of successful deployment was
95.9%.
In this trial the 30-day and 9-month mortality rates were
1.4% and 4.1%, respectively. These mortality rates are
comparable with those reported in the recent literature.21-25
The 30-day and 9-month myocardial infarction rates ob-
served in the EPIC trial (1.4% and 2.7%, respectively)
were similar to those cited in the published medical literature
(2.8% and 4.9%, respectively) for comparable follow-up
periods.12,23,25-27
A total of 12 target vessel revascularization procedures
were performed in 220 patients with 440 index grafts en-
rolled in the EPIC trial. Four of the 12 target vessel revascu-
larizations occurred in PAS-Port grafts and were deemed
possibly related to the device. By comparison, 8 of the 12
target vessel revascularizations were performed in target
vessels revascularized with hand-sewn index grafts. The
overall 30-day and 9-month target vessel revascularization
rates in this study are 0.9% and 2.7%, respectively, using
the total number of index grafts as the denominator. This
is comparable with published reports.12,23,26-28 Importantly,
3 early perioperative strokes occurred, all in patients who
underwent aortic clamping for the creation of the hand-
sewn graft.
Limitations
Different surgical and revascularization strategies, such as
distal target selection, degree of native coronary stenosis,
technique of vein harvest, and off-pump versus on-pump ap-
proaches, might influence graft patency. In addition, the
TABLE 7. Patency according to PREVENT IV definitions (<75%
stenosis)12
PAS-Port Hand-sewn
Intent-to-treat (angio only)
Grafts evaluated 186 191
Stenosis<75% 84.9% 83.8%
Stenosis 75%–99% 0% 0.5%
Occluded 15.1% 15.7%The Journal of Thoracic and Cindividual effect of each treatment (PAS-Port vs hand-
sewn) on MACEs is difficult to assess because each patient
received both treatments. However, the MACE rates in the
study population as a whole compare favorably with those
seen in published reports. Although the primary end point
was graft patency (angiographically assessed at 9 months)
in the per-protocol population and this analysis included
only patients who received both a PAS-Port graft and
a hand-sewn graft, these limitations were addressed by the
intent-to-treat and as-treated patency analyses. However,
smaller degrees of proximal stenosis might have been under-
estimated with the core laboratory analysis mandated by the
FDA.
Another limitation is the heterogeneity of the study
groups. This study included patients revascularized with
on- and off-pump techniques, simple and sequential grafts,
and conventional and facilitating hand-sewn anastomoses.
The patency analyses in the hand-sewn cohort were not sub-
divided into those patients who received a traditional hand-
sewn anastomosis and those who received an anastomosis
with one of the facilitating devices (Maquet Heartstring or
Novare Enclose). Thus the effect of these different tech-
niques on 9-month patency was not assessed by the core
laboratory.
CONCLUSIONS
In conclusion, the PAS-Port system provides a safe and
effective alternative for construction of proximal vein graft
anastomoses to the ascending aorta. This device allows an
automated and rapid anastomosis with minimal aortic ma-
nipulation and can be used in patients undergoing off- or
on-pump coronary artery bypass surgery. Nine-month graft
patency results are noninferior to the traditional hand-sewn
technique. Ultimately, late angiographic follow-up would
be required to confirm comparable long-term vein graft
patency rates.
We thank our surgical and cardiology colleagues at each of the
participating sites who enrolled and cared for patients in this trial.
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